Skip to main content
. 2011 Oct 11;11:786. doi: 10.1186/1471-2458-11-786

Table 3.

Adverse events reported by participants who completed all study visits

Adverse Event Study Visits

4-week
n/n (%)
8-week
n/n (%)
12-week
n/n (%)
24-week
n/n (%)
Throat irritation* 11/34 (32,4%) 5/32 (15,6%) 5/30 (16,7%) 4/27 (14,8%)

Mouth Irritation* 7/34 (20,6%) 4/32 (12,5%) 3/30 (10,0%) 2/27 (7,4%)

Sore Throat 4/34 (11,8%) 1/32 (3,1%) 1/30 (3,3%) 0/27 (0,0%)

Dry cough 11/34 (32,4%) 6/32 (18,8%) 3/30 (10,0%) 3/27 (11,1%)

Dry mouth 3/34 (8,8%) 1/32 (3,1%) 1/30 (3,3%) 1/27 (3,7%)

Mouth ulcers 1/34 (2,9%) 1/32 (3,1%) 1/30 (3,3%) 0/27 (0,0%)

Dizziness§ 5/34 (14,7%) 2/32 (6,3%) 2/30 (6,7%) 1/27 (3,7%)

Headache 4/34 (11,8%) 2/32 (6,3%) 2/30 (6,7%) 1/27 (3,7%)

Nausea 5/34 (14,7%) 2/32 (6,3%) 1/30 (3,3%) 1/27 (3,7%)

* Throat and mouth irritation were described either as tickling, itching, or burning sensation

§ Dizziness, was also used to mean vertigo and light-headedness.